Please login to the form below

Versartis

This page shows the latest Versartis news and features for those working in and with pharma, biotech and healthcare.

Versartis crashes as VELOCITY trial veers off track

The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... Versartis disappointment has proved a fillip for rival company

Latest news

Pfizer/Opko's long-acting growth hormone misses mark in trial

Also in the running is Versartis, whose somavaratan (VRS-317) is in late-stage trials and was recently licensed to Teijin in Japan.

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

Deal Watch August 2016

252. Versartis. Teijin (JP). Licence Japan. Somavaratan, long-acting form of rhGH, for paediatric and adult growth hormone deficiency in phase II/III in Japan.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Versartis names chief financial officer

Joshua Brumm joins from Pharmacyclics. Versartis has named Joshua Brumm as its first chief financial officer. ... The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Account Director – Healthcare Advertising – London: Salary TBC

Home-based Medical Writer – Medical Education: Salary TBC

Scientific Director – Medical Communications: Salary TBC

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

EU Head of Business Development and Client Service: Exceptional packge and bonus

Programme/ Account Director - Healthcare PR - London: Salary TBC

Health Consultant - Brand Comms: Competitive Salary

Senior Digital Health Specialist – Global Agency: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Medical Writer: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Home-based Senior Medical Writer – Med Ed: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Director, Medical Education: Salary TBC

Creative/ Medical Writer: Circa £35, 000 With Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Manager, Medical Communications, London: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....